Scott Dreyer Sells 2,255 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Scott Dreyer sold 2,255 shares of the business’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the sale, the executive vice president now owns 124,421 shares in the company, valued at $3,732,630. This represents a 1.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Collegium Pharmaceutical Price Performance

COLL stock traded up $0.15 during mid-day trading on Tuesday, reaching $29.82. 333,477 shares of the company traded hands, compared to its average volume of 415,338. Collegium Pharmaceutical, Inc. has a 52-week low of $27.28 and a 52-week high of $42.29. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The company has a market capitalization of $938.91 million, a P/E ratio of 12.85 and a beta of 0.99. The company has a fifty day moving average price of $30.88 and a 200-day moving average price of $32.87.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. As a group, analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Analyst Ratings Changes

COLL has been the topic of a number of research reports. Piper Sandler lowered their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a report on Friday, January 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $43.60.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. New Age Alpha Advisors LLC purchased a new position in shares of Collegium Pharmaceutical during the fourth quarter worth about $40,000. TD Private Client Wealth LLC grew its holdings in shares of Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 483 shares in the last quarter. KBC Group NV grew its holdings in shares of Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after purchasing an additional 982 shares in the last quarter. Virtus Fund Advisers LLC boosted its stake in Collegium Pharmaceutical by 30.5% in the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 565 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 316 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.